Richard MBA - Oncorus Chief CFO
| ONCRDelisted Stock | USD 0.04 0.01 14.71% |
Insider
Richard MBA is Chief CFO of Oncorus
| Age | 54 |
| Phone | 857 320 6400 |
| Web | https://www.oncorus.com |
Oncorus Management Efficiency
The company has return on total asset (ROA) of (0.3224) % which means that it has lost $0.3224 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2456) %, meaning that it created substantial loss on money invested by shareholders. Oncorus' management efficiency ratios could be used to measure how well Oncorus manages its routine affairs as well as how well it operates its assets and liabilities.Oncorus currently holds 70.65 M in liabilities with Debt to Equity (D/E) ratio of 0.72, which is about average as compared to similar companies. Oncorus has a current ratio of 6.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Oncorus' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MBA | Pyxis Oncology | 51 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Marcel CPA | Altamira Therapeutics | 66 | |
| Pamela MBA | Pyxis Oncology | 62 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| David Dornan | Elevation Oncology | 46 | |
| Balu Balasubramanian | Pyxis Oncology | N/A | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| Joseph Ferra | Elevation Oncology | 49 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Jan Pinkas | Pyxis Oncology | N/A | |
| Covadonga Paeda | Altamira Therapeutics | N/A | |
| Valerie MD | Elevation Oncology | 46 | |
| Martina BS | Pyxis Oncology | 59 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
Management Performance
| Return On Equity | -1.25 | |||
| Return On Asset | -0.32 |
Oncorus Leadership Team
Elected by the shareholders, the Oncorus' board of directors comprises two types of representatives: Oncorus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncorus. The board's role is to monitor Oncorus' management team and ensure that shareholders' interests are well served. Oncorus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncorus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard MBA, Chief CFO | ||
| Brian Shea, Director Sec | ||
| Chris German, Controller | ||
| Stephen Harbin, COO Staff | ||
| Mitchell Finer, NonEx Chairman | ||
| John MD, Chief Officer |
Oncorus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncorus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.25 | |||
| Return On Asset | -0.32 | |||
| Current Valuation | 25.71 M | |||
| Shares Outstanding | 26.09 M | |||
| Shares Owned By Insiders | 12.69 % | |||
| Shares Owned By Institutions | 55.29 % | |||
| Number Of Shares Shorted | 447.72 K | |||
| Price To Book | 0.13 X | |||
| EBITDA | (75.42 M) | |||
| Net Income | (77.42 M) |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Oncorus Stock
If you are still planning to invest in Oncorus check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncorus' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Transaction History View history of all your transactions and understand their impact on performance |